keyword
https://read.qxmd.com/read/38467886/assessment-of-ctla-4-gene-expression-levels-on-cd8-%C3%A2-t-cells-in-renal-transplant-patients-and-relation-with-serum-sctla-4-levels
#1
JOURNAL ARTICLE
Burcu Çerçi Alkaç, Mustafa Soyöz, Melek Pehlivan, Tülay Kılıçaslan Ayna, Erhan Tatar, H İlayhan Karahan Çöven, Mehmet Tanrısev, İbrahim Pirim
CTLA-4 (Cytotoxic T Lymphocyte Antigen-4) is an immune regulator molecule that is expressed on a variety of immune cells, including CD4+ and CD8+ T cells. After realizing the significance of this regulator molecule, researchers began to concentrate on its activation or inhibition in cancer. Even though there have been some studies on organ transplantation and autoimmunity, the role of the CTLA-4 molecule in renal transplantation has not been demonstrated. The goal of this study was to see how CTLA-4 gene expression and serum sCTLA-4 levels affected renal transplant patients...
March 11, 2024: Biochemical Genetics
https://read.qxmd.com/read/38380348/extracorporeal-photopheresis-reduces-fibrotic-and-inflammatory-transcriptomic-biological-marker-of-chronic-antibody-mediated-kidney-rejection
#2
JOURNAL ARTICLE
Arnaud Lionet, Marine Van Triempon, Martin Figeac, Victor Fages, Jean-Baptiste Gibier, François Provot, Mehdi Maanaoui, Nicolas Pottier, Christelle Cauffiez, François Glowacki
BACKGROUND: The benefit of extracorporeal photopheresis on the course of kidney transplant rejection is unknown. The aim of our study was to investigate the variations in transcriptomics on graft biopsies when extracorporeal photopheresis was used to treat chronic humoral rejection after kidney transplantation. METHODS: We retrospectively analyzed the mRNA expression of 770 genes of interest in graft biopsies performed before and after treatment. Eight patients received an average of 23 extracorporeal photopheresis sessions over 4 mo between the 2 biopsies...
March 2024: Transplantation Direct
https://read.qxmd.com/read/38371002/evaluating-kaposi-sarcoma-in-kidney-transplant-patients-a-systematic-review-and-meta-analysis
#3
REVIEW
Sakditad Saowapa, Natchaya Polpichai, Pharit Siladech, Chalothorn Wannaphut, Manasawee Tanariyakul, Phuuwadith Wattanachayakul, Pakin Lalitnithi
Kaposi's sarcoma (KS) is a malignancy that commonly appears as lesions on the skin or mucosal surfaces but can also develop in other organs. This cancer is usually caused by the human herpesvirus 8 (HHV-8), recently known as Kaposi's sarcoma-associated herpesvirus (KSHV). KS is rare in the general population but can develop in kidney transplant recipients with varying incidence due to immunocompromised status from immunosuppression. The main aim of the present systematic review was to identify the prevalence and treatment of KS in kidney transplant patients...
January 2024: Curēus
https://read.qxmd.com/read/38345405/novel-indications-for-referral-and-care-for-simultaneous-liver-kidney-transplant-recipients
#4
JOURNAL ARTICLE
Erik L Lum, Suphamai Bunnapradist, Alexander C Wiseman, Ahmet Gurakar, Antoney Ferrey, Uttam Reddy, Fawaz Al Ammary
PURPOSE OF REVIEW: Kidney dysfunction is challenging in liver transplant candidates to determine whether it is reversible or not. This review focuses on the pertinent data on how to best approach liver transplant candidates with kidney dysfunction in the current era after implementing the simultaneous liver kidney (SLK) allocation policy and safety net. RECENT FINDINGS: The implementation of the SLK policy inverted the steady rise in SLK transplants and improved the utilization of high-quality kidneys...
February 13, 2024: Current Opinion in Nephrology and Hypertension
https://read.qxmd.com/read/38252908/cemiplimab-for-kidney-transplant-recipients-with-advanced-cutaneous-squamous-cell-carcinoma
#5
JOURNAL ARTICLE
Glenn J Hanna, Harita Dharanesswaran, Anita Giobbie-Hurder, John J Harran, Zixi Liao, Lori Pai, Vatche Tchekmedyian, Emily S Ruiz, Abigail H Waldman, Chrysalyne D Schmults, Leonardo V Riella, Patrick Lizotte, Cloud P Paweletz, Anil K Chandraker, Naoka Murakami, Ann W Silk
PURPOSE: Cemiplimab is approved for treating locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). Solid organ transplant recipients have been excluded from immunotherapy trials, given concern for allograft rejection despite their increased risk of skin cancers. Chronic immunosuppression is necessary to prevent organ rejection but may attenuate antitumor response with PD-1 inhibitors. METHODS: We report a phase I study of cemiplimab for kidney transplant recipients (KTRs) with advanced CSCC...
January 22, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38193229/study-the-mrna-level-of-il-27-il-27r-pathway-molecules-in-kidney-transplant-rejection
#6
JOURNAL ARTICLE
Aftab Karimi, Ramin Yaghobi, Jamshid Roozbeh, Zahra Rahimi, Afsoon Afshari, Zahra Akbarpoor, Mojdeh Heidari
BACKGROUND: Renal transplantation stands as the sole remedy for individuals afflicted with end-stage renal diseases, and safeguarding them from transplant rejection represents a vital, life-preserving endeavor posttransplantation. In this context, the impact of cytokines, notably IL-27, assumes a critical role in managing immune responses aimed at countering rejection. Consequently, this investigation endeavors to explore the precise function of IL-27 and its associated cytokines in the context of kidney transplant rejection...
December 29, 2023: Archivio Italiano di Urologia, Andrologia
https://read.qxmd.com/read/37760879/biomarkers-for-kidney-transplant-rejection-a-short-review-study
#7
REVIEW
Israa Sharaby, Ahmed Alksas, Mohamed Abou El-Ghar, Mona Eldeeb, Mohammed Ghazal, Dibson Gondim, Ayman El-Baz
Kidney transplantation is the preferred treatment for end-stage renal failure, but the limited availability of donors and the risk of immune rejection pose significant challenges. Early detection of acute renal rejection is a critical step to increasing the lifespan of the transplanted kidney. Investigating the clinical, genetic, and histopathological markers correlated to acute renal rejection, as well as finding noninvasive markers for early detection, is urgently needed. It is also crucial to identify which markers are associated with different types of acute renal rejection to manage treatment effectively...
August 31, 2023: Biomedicines
https://read.qxmd.com/read/37759601/the-long-scientific-journey-of-sirolimus-rapamycin-from-the-soil-of-easter-island-rapa-nui-to-applied-research-and-clinical-trials-on-%C3%AE-thalassemia-and-other-hemoglobinopathies
#8
REVIEW
Roberto Gambari, Cristina Zuccato, Lucia Carmela Cosenza, Matteo Zurlo, Jessica Gasparello, Alessia Finotti, Maria Rita Gamberini, Marco Prosdocimi
In this review article, we present the fascinating story of rapamycin (sirolimus), a drug able to induce γ-globin gene expression and increased production of fetal hemoglobin (HbF) in erythroid cells, including primary erythroid precursor cells (ErPCs) isolated from β-thalassemia patients. For this reason, rapamycin is considered of great interest for the treatment of β-thalassemia. In fact, high levels of HbF are known to be highly beneficial for β-thalassemia patients. The story of rapamycin discovery began in 1964, with METEI, the Medical Expedition to Easter Island (Rapa Nui)...
September 2, 2023: Biology
https://read.qxmd.com/read/37751051/calcineurin-and-mtor-inhibitors-in-kidney-transplantation-integrative-metamodeling-on-transplant-survival-and-kidney-function
#9
JOURNAL ARTICLE
Hina Khalid, Muhammad Mazhar Fareed, Thomas Dandekar, Sergey Shityakov
In our study, we examined the efficacy of mTOR (mammalian target of rapamycin) inhibitors, specifically rapamycin (Rap), compared to calcineurin inhibitors (CNIs) in kidney transplantation. By conducting a comprehensive search across reputable databases (EMBASE, Scopus, PubMed, Cochrane, and Crossref), we gathered data for a six-month post-transplantation period. Our analysis revealed that mTOR inhibitor administration resulted in improved glomerular filtration rate (GFR) and serum creatinine levels. However, it is important to note that the mTOR inhibitor group had a higher incidence of acute rejection after biopsy...
September 26, 2023: International Urology and Nephrology
https://read.qxmd.com/read/37732393/donor-derived-cell-free-dna-as-a-biomarker-in-kidney-transplantation
#10
REVIEW
Tarek Abdulhadi, Louai Alrata, Casey Dubrawka, Gwendolyn Amurao, Sri Mahathi Kalipatnapu, Che Isaac, Shelden Rodrigues, Karen Marie Flores, Dema Yaseen Alsabbagh, Omar Alomar, Tarek Alhamad
The early detection of acute rejection in the allograft is important as it provides an opportunity for timely therapeutic intervention in order to preserve graft function and achieve longer graft survival. Donor-derived cell-free DNA (dd-cfDNA) has emerged as a new biomarker in the field of kidney transplantation. In this review, we used data from various studies to examine the role of dd-cfDNA in comparison to creatinine and donor-specific antibodies in the early detection of transplant rejection. We also reviewed the use of dd-cfDNA in other organ transplants as well as the challenges and potential future direction for dd-cfDNA as a diagnostic tool...
September 21, 2023: Pharmacogenomics
https://read.qxmd.com/read/37667551/the-role-of-regulatory-t-cells-in-the-pathogenesis-of-acute-kidney-injury
#11
JOURNAL ARTICLE
Xiaoyou Liu, Jianmin Hu, Guorong Liao, Ding Liu, Song Zhou, Jie Zhang, Jun Liao, Zefeng Guo, Yuzhu Li, Siqiang Yang, Shichao Li, Hua Chen, Ying Guo, Min Li, Lipei Fan, Liuyang Li, Ming Zhao, Yongguang Liu
The incidence of acute kidney injury (AKI) is on the rise and is associated with high mortality; however, there are currently few effective treatments. Moreover, the relationship between Tregs and other components of the immune microenvironment (IME) in the pathogenesis of AKI remains unclear. We downloaded four publicly accessible AKI datasets, GSE61739, GSE67401, GSE19130, GSE81741, GSE19288 and GSE106993 from the gene expression omnibus (GEO) database. Additionally, we gathered two kidney single-cell sequencing (scRNA-seq) samples from the Department of Organ Transplantation at Zhujiang Hospital of Southern Medical University to investigate chronic kidney transplant rejection (CKTR)...
September 4, 2023: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/37632118/associations-of-serum-calprotectin-arterial-stiffness-and-long-covid-symptoms-in-dalmatian-kidney-transplant-recipients
#12
JOURNAL ARTICLE
Tina Đogaš, Ivana Novak, Marija Babić, Marijana Vučković, Leida Tandara, Josipa Radić
We aimed to explore long COVID symptoms, serum calprotectin levels, and the parameters of arterial stiffness in Dalmatian kidney transplant recipients (KTRs) and their possible associations. A cross-sectional, single-center case-control study on 98 KTRs who had recovered from COVID-19 was performed. Long COVID symptoms were explored via standardized questionnaires assessing quality of life, and serum calprotectin was also measured. Out of 98 KTRs with a mean age of 62 years, 63 (64.3%) were men. Medical history, clinical and laboratory parameters, and arterial stiffness measurements were obtained for each study participant...
August 21, 2023: Viruses
https://read.qxmd.com/read/37620431/belatacept-inhibit-human-b-cell-germinal-center-development-in-immunodeficient-mice
#13
JOURNAL ARTICLE
Chloé Samson, Allan Thiolat, Anissa Moktefi, José L Cohen, Caroline Pilon, Philippe Grimbert
The humoral response mediated by alloantibodies directed against donor HLA molecules (DSAs) is one of the main causes of graft loss in kidney transplantation. Understanding the pathophysiology leading to humoral kidney rejection as the development of therapeutic tools is therefore a main objective in the field of solid organ transplantation and necessitate adapted experimental models. Among the immunosuppressive agents used in renal transplantation, belatacept, a fusion protein targeting T costimulatory molecules has shown its ability to prevent more efficiently the secretion of DSA by different mechanisms including a direct action on plasma cells but also on B lymphocytes and follicular helper T lymphocytes (Tfh) cooperation...
August 24, 2023: Scientific Reports
https://read.qxmd.com/read/37519536/angiotensin-ii-type-1-receptor-antibody-mediated-kidney-rejection-unresponsive-to-treatment
#14
David Allison, Zahraa Hajjiri, Luis Manon, Sally Campbell-Lee, Suhalika Sahni, Suman Setty
Allograft rejection is a significant cause of renal transplant failure which needs prompt diagnosis and treatment for graft salvage. Angiotensin II type 1 receptor antibody-mediated rejection (AT1R-AMR) is increasingly being identified as the etiology of antibody-mediated rejection in kidney transplant recipients with allograft rejection but without detectable human leukocyte antigen (HLA) antibodies. While some reports have suggested that AT1R-AMR may be refractory to standard therapy, others have reported improvement or stabilization of graft function...
June 2023: Curēus
https://read.qxmd.com/read/37511833/therapy-in-the-course-of-kidney-graft-rejection-implications-for-the-cardiovascular-system-a-systematic-review
#15
REVIEW
Jakub Mizera, Justyna Pilch, Ugo Giordano, Magdalena Krajewska, Mirosław Banasik
Kidney graft failure is not a homogenous disease and the Banff classification distinguishes several types of graft rejection. The maintenance of a transplant and the treatment of its failure require specific medications and differ due to the underlying molecular mechanism. As a consequence, patients suffering from different rejection types will experience distinct side-effects upon therapy. The review is focused on comparing treatment regimens as well as presenting the latest insights into innovative therapeutic approaches in patients with an ongoing active ABMR, chronic active ABMR, chronic ABMR, acute TCMR, chronic active TCMR, borderline and mixed rejection...
June 27, 2023: Life
https://read.qxmd.com/read/37506983/rituximab-associated-pres-in-antibody-mediated-kidney-rejection-a-case-report
#16
M D Masoud Etemadifar, Seyyed-Ali Alaei, Elahe Saffari, M D Mehri Salari
Posterior Reversible Encephalopathy Syndrome (PRES) is a rare neurological disorder with a wide range of neurological symptoms. Different risk factors are known for PRES in patients with a history of kidney transplantation; these patients developing PRES were associated with immunosuppressants and cytotoxic drug therapies, including reports of rituximab therapy. Herein, we report a case of rituximab-associated PRES in the context of antibody-mediated kidney allograft rejection. A 29-year-old male patient with antibody-mediated kidney rejection was treated with rituximab, and then he developed PRES...
July 26, 2023: Transplant Immunology
https://read.qxmd.com/read/37445781/microchimerism-as-post-transplant-marker-of-a-chronic-rejection-process
#17
JOURNAL ARTICLE
Jerzy Sieńko, Maciej Kotowski, Wiktoria Czarnecka, Albert Podkówka, Karol Tejchman, Katarzyna Kotfis, Samir Zeair, Zenon Czajkowski, Karolina Skonieczna-Żydecka
The risk of losing a transplanted organ is high, and non-invasive markers to warn of this phenomenon are still being sought. We investigated the impact of post-transplant microchimerism on the function of the transplanted kidney. The study included 100 kidney transplant recipients, mostly women. All transplanted organs were from opposite-sex deceased donors. Microchimerism was assessed using multiplex PCR. Male DNA was detected in all urine samples from female recipients and in 13/56 blood samples from female kidney recipients...
June 25, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37165330/public-values-and-guiding-principles-for-implementing-epitope-compatibility-in-kidney-transplantation-allocation-criteria-results-from-a-canadian-online-public-deliberation
#18
JOURNAL ARTICLE
Caitlin Slomp, Louisa Edwards, Michael Burgess, Ruth Sapir-Pichhadze, Paul Keown, Stirling Bryan
BACKGROUND: Epitope compatibility in deceased donor kidney allocation is an emerging area of precision medicine (PM), seeking to improve compatibility between donor kidneys to transplant candidates in the hope of avoiding kidney rejection. Though the potential benefits of using epitope compatibility are promising, the implied modification of deceased organ allocation criteria requires consideration of significant clinical and ethical trade-offs. As a matter of public policy, these trade-offs should consider public values and preferences...
May 10, 2023: BMC Public Health
https://read.qxmd.com/read/36969159/integrated-analysis-of-cell-specific-gene-expression-in-peripheral-blood-using-isg15-as-a-marker-of-rejection-in-kidney-transplantation
#19
JOURNAL ARTICLE
Zijian Zhang, Yan Qin, Yicun Wang, Shuai Li, Xiaopeng Hu
BACKGROUND: Allograft kidney rejection can lead to graft dysfunction and graft loss. Protocol biopsy poses additional risk for recipients with normal renal function. The transcriptome of peripheral blood mononuclear cells (PBMCs) contains tremendous information and has potential application value for non-invasive diagnosis. METHODS: From the Gene Expression Omnibus database, we collected three datasets containing 109 rejected samples and 215 normal controls. After data filter and normalization, we performed deconvolution of bulk RNA sequencing data to predict cell type and cell-type specific gene expression...
2023: Frontiers in Immunology
https://read.qxmd.com/read/36814924/diagnosis-of-t-cell-mediated-kidney-rejection-by-biopsy-based-proteomic-biomarkers-and-machine-learning
#20
JOURNAL ARTICLE
Fei Fang, Peng Liu, Lei Song, Patrick Wagner, David Bartlett, Liane Ma, Xue Li, M Amin Rahimian, George Tseng, Parmjeet Randhawa, Kunhong Xiao
BACKGROUND: Biopsy-based diagnosis is essential for maintaining kidney allograft longevity by ensuring prompt treatment for graft complications. Although histologic assessment remains the gold standard, it carries significant limitations such as subjective interpretation, suboptimal reproducibility, and imprecise quantitation of disease burden. It is hoped that molecular diagnostics could enhance the efficiency, accuracy, and reproducibility of traditional histologic methods. METHODS: Quantitative label-free mass spectrometry analysis was performed on a set of formalin-fixed, paraffin-embedded (FFPE) biopsies from kidney transplant patients, including five samples each with diagnosis of T-cell-mediated rejection (TCMR), polyomavirus BK nephropathy (BKPyVN), and stable (STA) kidney function control tissue...
2023: Frontiers in Immunology
keyword
keyword
92005
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.